Mutationally activated RAS proteins are critical oncogenic drivers in nearly 30% of all human
cancers. As with mutant RAS, the role of wild type RAS proteins in oncogenesis, tumour …

Cancer evolution is a stochastic process both at the genome and gene levels. Most of
tumors contain multiple genetic subclones, evolving in either succession or in parallel, either …

Silencing of tumor-suppressor genes (TSGs) by DNA promoter hypermethylation is an early
event in carcinogenesis; hence, TSGs may serve as early tumor biomarkers. We determined …

RASSF2 can bind directly to K‐Ras and function as a negative effector of Ras protein.
RASSF2A is the only isoform of RASSF2 that contains CpG islands in its promoter and it has …

Epigenetic aberration is known to be important in human carcinogenesis. Promoter
methylation status of RAS effector related genes, RASSF1A, RASSF2A, hDAB2IP (m2a and …

Based on seroepidemiological studies, human herpes simplex virus types 1 and 2 (HSV-1,
HSV-2) are put in relation with a number of cancer diseases; however, they do not appear to …

Objective: The tumor suppressor gene, Ras-association domain family (RASSF) 2A, is
inactivated by promoter hypermethylation in many cancers. The current study was performed …

Regulator of G protein signaling 14 (RGS14) is a multifunctional scaffolding protein that
integrates heterotrimeric G protein and H-Ras signaling pathways. RGS14 possesses an …

Background Epigenetic silencing of tumor suppressor genes associated with promoter
methylation is considered to be a hallmark of oncogenesis. RASSF1A is a candidate tumor …

Esophageal squamous-cell carcinoma (ESCC) is an invasive neoplastic disease generally
associated with poor survival rates. The incidence of ESCC is characterized by marked …